| Trial ID: | L6739 |
| Source ID: | NCT02210871
|
| Associated Drug: |
Semaglutide
|
| Title: |
Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2|Hepatic Impaired
|
| Interventions: |
DRUG: semaglutide
|
| Outcome Measures: |
Primary: Area under the semaglutide plasma concentration-time curve, Day 1 - day 36 | Secondary: Maximum observed semaglutide plasma concentration, Day 1 - day 36|Number of treatment emergent adverse events (TEAEs), Day 1 - day 36
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
44
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2014-08-07
|
| Completion Date: |
2015-06-03
|
| Results First Posted: |
|
| Last Update Posted: |
2017-12-21
|
| Locations: |
Novo Nordisk Investigational Site, Warszawa, 02-507, Poland|Novo Nordisk Investigational Site, Wolomin, 05-200, Poland|Novo Nordisk Investigational Site, Bratislava, 83101, Slovakia|Novo Nordisk Investigational Site, Bratislava, 833 05, Slovakia
|
| URL: |
https://clinicaltrials.gov/show/NCT02210871
|
